ATE367167T1 - Aufbereitung von aldesleukin zur pharmazeutischen verwendung - Google Patents

Aufbereitung von aldesleukin zur pharmazeutischen verwendung

Info

Publication number
ATE367167T1
ATE367167T1 AT05250680T AT05250680T ATE367167T1 AT E367167 T1 ATE367167 T1 AT E367167T1 AT 05250680 T AT05250680 T AT 05250680T AT 05250680 T AT05250680 T AT 05250680T AT E367167 T1 ATE367167 T1 AT E367167T1
Authority
AT
Austria
Prior art keywords
aldesleukin
sds
pharmaceutical use
preparation
give
Prior art date
Application number
AT05250680T
Other languages
English (en)
Inventor
Maninder Hora
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE367167T1 publication Critical patent/ATE367167T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT05250680T 2005-02-07 2005-02-07 Aufbereitung von aldesleukin zur pharmazeutischen verwendung ATE367167T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05250680A EP1688146B1 (de) 2005-02-07 2005-02-07 Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung

Publications (1)

Publication Number Publication Date
ATE367167T1 true ATE367167T1 (de) 2007-08-15

Family

ID=34940439

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05250680T ATE367167T1 (de) 2005-02-07 2005-02-07 Aufbereitung von aldesleukin zur pharmazeutischen verwendung

Country Status (10)

Country Link
EP (1) EP1688146B1 (de)
AT (1) ATE367167T1 (de)
CY (1) CY1108521T1 (de)
DE (1) DE602005001688T2 (de)
DK (1) DK1688146T3 (de)
ES (1) ES2289663T3 (de)
HR (1) HRP20070487T3 (de)
PL (1) PL1688146T3 (de)
PT (1) PT1688146E (de)
SI (1) SI1688146T1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010134091A1 (en) * 2009-05-20 2010-11-25 M/S. Provimi Animal Nutrition India Private Limited A process for preparation of a non-antibiotic growth promoter formula / product and its use in food animals
KR20200070407A (ko) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
EP2925297B1 (de) 2012-11-02 2017-06-21 CyTuVax Zusammensetzung enthaltend zytokin makroaggregate
EP3482766B1 (de) 2014-08-11 2020-05-20 Delinia, Inc. Modifizierte il-2-varianten zur selektiven aktivierung regulatorischer t-zellen zur behandlung von autoimmunerkrankungen
US12233104B2 (en) 2015-10-08 2025-02-25 Nektar Therapeutics Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
JP7038655B2 (ja) * 2015-10-22 2022-03-18 イルトゥー・ファルマ Ｉｌ－２医薬組成物
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN110167957A (zh) 2016-11-08 2019-08-23 德里尼亚公司 用于治疗自身免疫疾病的il-2变体
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag IL2 antibody grafted proteins and methods of use in cancer treatment
KR20210021357A (ko) 2018-06-13 2021-02-25 아크론 바이오테크놀로지 엘엘씨 액체 약학적 조성물에서 매우 안정한 치료적으로 활성인 알데스루킨의 제조 방법
US11517685B2 (en) 2019-01-18 2022-12-06 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
EP3829370A4 (de) 2018-08-22 2022-04-27 Respira Technologies, Inc. Elektronische vorrichtung zur erzeugung eines aerosols zur inhalation durch eine person
US11690963B2 (en) 2018-08-22 2023-07-04 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
US12471625B2 (en) 2020-11-01 2025-11-18 Qnovia, Inc. Electronic devices and liquids for aerosolizing and inhaling therewith
CN116549609A (zh) 2022-01-27 2023-08-08 北京良远生物医药研究有限公司 一种il2制剂、其制备方法及应用
WO2023205385A1 (en) 2022-04-22 2023-10-26 Qnovia, Inc. Electronic devices for aerosolizing and inhaling liquid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2

Also Published As

Publication number Publication date
HRP20070487T3 (en) 2007-12-31
SI1688146T1 (sl) 2007-12-31
PL1688146T3 (pl) 2007-12-31
CY1108521T1 (el) 2014-04-09
DK1688146T3 (da) 2007-11-05
ES2289663T3 (es) 2008-02-01
DE602005001688T2 (de) 2008-04-10
EP1688146A1 (de) 2006-08-09
EP1688146B1 (de) 2007-07-18
DE602005001688D1 (de) 2007-08-30
PT1688146E (pt) 2007-10-29

Similar Documents

Publication Publication Date Title
CY1108521T1 (el) Παρασκευη αλδεσλευκινης για φαρμακευτικη χρηση
MX2022015040A (es) Proteina espicular (s) del coronavirus geneticamente manipulada y metodos de uso de la misma.
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
ATE473224T1 (de) Verfahren zur herstellung von nebivolol
GB2441939A (en) Surgical membrane
DE602006017732D1 (de) Verfahren zur herstellung von lyophilisiertem piperacillin-natrium in kombination mit tazobactam-natrium, mit verbesserter stabilität nach der rekonstitution
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
DE602005024206D1 (de) Verfahren zur Herstellung von hydrophilen Kohlenstoffnanoröhren
DE602005018981D1 (de) Verfahren zur Herstellung von L-Cystein, und L-Cystein-produzierender Mikroorganismus
ATE497521T1 (de) Polymerblends zur herstellung von folien mit reduzierter defektzahl
ATE551381T1 (de) Verfahren zur herstellung von hochkonzentrierte pelletierte additivkonzentrate für polymer
BRPI0721984B8 (pt) interferon-2b peguilado (ifn-2b), seu método de preparo e de purificação, composição, bem como uso dos mesmos
DE602006016735D1 (de) Verfahren zur proliferation von stammzellen
DE102005001078A8 (de) Glaspulver, insbesondere biologisch aktives Glaspulver und Verfahren zur Herstellung von Glaspulver, insbesondere biologisch aktivem Glaspulver
ATE486841T1 (de) Verfahren zur herstellung von pregabalin und salzen daraus
ATE537173T1 (de) Verfahren zur herstellung von cucurbiturilen
TWI371446B (en) Novel compounds, their preparation and use
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
DE50304242D1 (de) Verfahren zur herstellung von acylphosphinoxiden
EP1845941A4 (de) Sirupzusammensetzung mit dexibupropen als aktivem bestandteil und verfahren zur herstellung davon
DE602005016282D1 (de) Verfahren zur herstellung von camptothecin-derivaten
ATE385252T1 (de) Verfahren zur herstellung von granulatförmigen zusammensetzungen
FR2909255B1 (fr) Utilisation d'herbes aquatiques a titre de support de culture hors-sol et support ainsi constitue
ATE451109T1 (de) Medizinische lösung; verfahren zur herstellung dieser lösung und ihre verwendung
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide